Plasma Protease C1 Inhibitor Market to grow at a CAGR of 7.55% during 2024-2028
The Plasma Protease C1 Inhibitor Market is expected to grow at a CAGR of 7.55% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 2.00 billion. In the medical field, Bradykinin is a significant inflammatory mediator implicated in various pathological conditions, most notably angioedema. Plasma protease C1 inhibitors serve a critical role in regulating the activation of the complement and contact systems, which in turn influences bradykinin production. However, in hereditary angioedema (HAE), the levels of plasma protease C1 inhibitors are insufficient, leading to uncontrolled bradykinin release and subsequent angioedema symptoms. To mitigate these symptoms, Bradykinin B2 receptor antagonists have emerged as an effective therapeutic solution. These antagonists inhibit the activation of B2 receptors by bradykinin, thereby reducing its effects and preventing angioedema attacks. The increasing adoption of Bradykinin B2 receptor antagonists in the global plasma protease C1 inhibitor market is driven by their proven efficacy in managing HAE symptoms and preventing future episodes.
Get more information on Plasma Protease C1 Inhibitor Market by requesting a sample report
Technavio analysts predict that the Hospital pharmacy subsegment will lead the End-user segment during 2024 and 2028 The hospital pharmacy sector holds a pivotal position in the global plasma protease C1 inhibitor market, with hospital pharmacies being instrumental in procuring, storing, and dispensing this essential medication to patients. The expanding prevalence of hereditary angioedema (HAE) globally is a primary growth driver for the hospital pharmacy segment in this market. As the number of HAE diagnoses rises, so does the demand for plasma protease C1 inhibitors, offering significant business opportunities for hospital pharmacies to address the medication requirements of these patients. Moreover, hospital pharmacies play a vital role in ensuring the accessibility and availability of these life-saving medications for HAE patients.
Here are the various ways based on which the market is segmented:
There are several factors that are causing the market to flourish increasing research and development in plasma protease c1 inhibitor
Learn which are the obstacles that the market is experiencing in the way of its growth by accessing the free PDF report
Title: Plasma Protease C1 Inhibitor Market: A Statistical Analysis of C1-INH Complexes and Their Role in Angioedema The Plasma Protease C1 Inhibitor (C1-INH) market is witnessing significant growth due to the increasing prevalence of C1-INH deficiency, a rare genetic disorder characterized by the lack of this essential serine protease inhibitor. C1-INH plays a crucial role in regulating the complement system and the coagulation cascade by inhibiting the activation complexes of C1 and plasma kallikrein. Blood samples are collected from patients to quantitatively compare plasma concentrations of C1-INH during HAE attacks and symptom-free periods. ELISA is the most commonly used technique for C1-INH quantification. The activation of C1-INH leads to the formation of C1-INH complexes, which can be further studied to understand the pathogenesis of angioedema. The fibrinolytic system, including thrombin and plasmin, also plays a role in angioedema. Antiplasmin agents are used to inhibit plasmin and prevent the degradation of fibrin clots. The Plasma enzyme systems market is expected to grow due to the increasing demand for C1-INH replacement therapy. While discussing the Plasma Protease C1 Inhibitor market, it is essential to differentiate it from the toy sector, which includes collectibles, construction toys like Playmobil and Lego, multi-brand games, toy rental, and second-hand toys. However, there is no direct relationship between the two markets. Kidults, a growing demographic, contribute significantly to the toy sector's e-commerce sales. In conclusion, the Plasma Protease C1 Inhibitor market's growth is driven by the increasing prevalence of C1-INH deficiency and the demand for replacement therapy. Statistical analysis of C1-INH complexes and their role in angioedema can provide valuable insights into the disease's pathogenesis and potential therapeutic targets.
According to Technavio, the global Plasma Protease C1 Inhibitor Market is a segment of the larger USDX billion pharmaceuticals industry within the healthcare sector. This market encompasses entities involved in the research, development, and manufacturing of various pharmaceutical offerings, including generic and non-generic drugs, as well as veterinary medications. The healthcare industry's overall size is determined by the consolidated revenue generated by providers of equipment, pharmaceuticals, biotechnology, life sciences tools, and services. Factors driving the growth of the pharmaceuticals market include the increasing elderly population, with the global population aged 60 and above projected to significantly expand.
The Plasma Protease C1 Inhibitor Market is experiencing significant growth, fueled by the increasing research and development in plasma protease c1 inhibitor. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
